These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 463894)

  • 1. Improved methods for estimating initial heparin infusion rates.
    Chenella FC; Gill MA; Kern JW; Floyd RA; McGehee WG
    Am J Hosp Pharm; 1979 Jun; 36(6):782-4. PubMed ID: 463894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate use of heparin. Empiric vs nomogram-based dosing.
    Gunnarsson PS; Sawyer WT; Montague D; Williams ML; Dupuis RE; Caiola SM
    Arch Intern Med; 1995 Mar; 155(5):526-32. PubMed ID: 7864708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time.
    Groce JB; Gal P; Douglas JB; Steuterman MC
    Clin Pharm; 1987 Mar; 6(3):216-22. PubMed ID: 3665377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal model for pharmacokinetic approach to individualized heparin dosage regimen for i.v. infusion by constant rate to achieve and maintain a desired clotting time.
    Ritschel WA; Brady ME
    Arzneimittelforschung; 1979; 29(12):1891-4. PubMed ID: 546429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
    Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
    Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of heparin in males and females.
    Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
    Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.
    White RH; Zhou H; Woo L; Mungall D
    Arch Intern Med; 1997 Nov; 157(21):2468-72. PubMed ID: 9385298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of a first-order model for estimating initial heparin dosage.
    Joch LE; Lutomski DM; Williams DJ; Bottorff M
    Clin Pharm; 1993 Aug; 12(8):597-601. PubMed ID: 8222524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization and effectiveness of a weight-based heparin nomogram at a large academic medical center.
    Balcezak TJ; Krumholz HM; Getnick GS; Vaccarino V; Lin ZQ; Cadman EC
    Am J Manag Care; 2000 Mar; 6(3):329-38. PubMed ID: 10977433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a modified dosing weight for heparin therapy in a morbidly obese patient.
    Schwiesow SJ; Wessell AM; Steyer TE
    Ann Pharmacother; 2005 Apr; 39(4):753-6. PubMed ID: 15741422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation.
    Shalansky KF; FitzGerald JM; Sunderji R; Traboulay SJ; O'Malley B; McCarron BI; Naiman S
    Pharmacotherapy; 1996; 16(6):1076-84. PubMed ID: 8947981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control and complications of intermittent heparin therapy.
    Norman CS; Provan JL
    Surg Gynecol Obstet; 1977 Sep; 145(3):338-42. PubMed ID: 888052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.